Orion Oyj (OTCMKTS:ORINY) Plans Dividend of $0.45

Orion Oyj (OTCMKTS:ORINY) announced a dividend on Monday, March 17th, NASDAQ Dividends reports. Investors of record on Monday, April 7th will be given a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date of this dividend is Monday, April 7th. This is a 86.2% increase from Orion Oyj’s previous dividend of $0.24.

Orion Oyj Stock Performance

ORINY stock remained flat at $29.76 during mid-day trading on Tuesday. The company’s stock had a trading volume of 115 shares, compared to its average volume of 3,410. The stock has a market cap of $8.40 billion, a PE ratio of 23.62 and a beta of 0.25. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. Orion Oyj has a 12 month low of $17.50 and a 12 month high of $30.25. The business’s fifty day moving average price is $26.81 and its two-hundred day moving average price is $25.49.

Orion Oyj (OTCMKTS:ORINY) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. The firm had revenue of $463.41 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, sell-side analysts expect that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Nordea Equity Research downgraded shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.